The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Osteoprotegerin and RANK ligand expression in prostate cancer.
Abstract
Objectives To investigate the expression of osteoprotegerin (OPG) and RANK ligand (RANKL) in human prostatic tissues. The factors regulating the increased turnover associated with prostate cancer (CaP) bone metastasis are unknown. OPG and RANKL are recently identified regulators of bone resorption and bone remodeling.Methods Tissues from 28 patients with CaP and from 4 normal organ donors were analyzed by reverse transcriptase-polymerase chain reaction and immunohistochemistry for the expression of OPG and RANKL.Results OPG and RANKL messages were detected in both normal and cancerous prostate samples. In the normal prostate, OPG protein was detected in luminal epithelial and stromal cells (5% to 65% and 15% to 70%, respectively) and RANKL immunoreactivity was observed in 15% to 50% of basal epithelial cells, 40% to 90% of luminal epithelial cells, and 70% to 100% of stromal cells. OPG was not detected in 8 of 10 primary CaP specimens; RANKL was heterogeneously expressed in 10 of 11 CaP specimens. The percentage of tumor cells expressing OPG and RANKL was significantly increased in all CaP bone metastases compared with nonosseous metastases or primary CaP.Conclusions CaP bone metastases were consistently immunoreactive for both OPG and RANKL compared with nonosseous metastases or primary CaP. The presence of these crucial bone resorption regulators in CaP bone metastases suggests a mechanism whereby CaP cells may modulate bone turnover and has profound implications for the establishment and development of CaP bone metastases in advanced disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“prostate cancer cells (CaP) (314 -316) and MM cells (317-322) have been shown to express RANKL directly.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [315]
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,224
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
RANK is essential for osteoclast and lymph node development.
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S. D., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,183
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Cited by 650
Hofbauer, L. C., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., Riggs, B. L., & Khosla, S. (1999) · Bone · doi:10.1016/s8756-3282(99)00162-3 · Cited by 630
Honoré, P., Luger, N. M., Sabino, M. A. C., Schwei, M. J., Rogers, S. D., Mach, D. B., O'keefe, P. F., Ramnaraine, M. L. R., Clohisy, D. R., & Mantyh, P. W. (2000) · Nature Medicine · doi:10.1038/74999 · Cited by 497
Cited by
Sorted by citations
Items 201–234 of 234
Biology and Pathophysiology of Bone Metastasis in Prostate Cancer
Bertoldo, F. (2016) · Springer eBooks · doi:10.1007/978-3-319-42327-2_1 · Cited by 1
[Advances in molecular mechanisms of bone invasion by oral cancer].
Liu, W., Li, C.-J., & Li, L.-J. (2021) · PubMed Central · doi:10.7518/hxkq.2021.02.015 · Cited by 1
Pasquini, L., & Morris, M. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-39005-0_19 · Cited by 1
Tumor-Bone Cell Interactions in Bone Metastases
Fournier, P. G. J., Dunn, L. K., Clines, G. A., & Guise, T. A. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374895-9.00002-5 · Cited by 1
Einfluss von GnRH Analoga auf die Metastasierung humaner Mammakarzinomzellen in vitro und in vivo
Schubert, A. (2010) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-411 · Cited by 1
Pathophysiology of Prostate Cancer Bone Metastasis
Keller, E. T., & Hall, C. L. (2010) · Springer eBooks · doi:10.1007/978-1-60327-829-4_22 · Cited by 1
RANKL: Targeting bone and cancer to treat skeletal complications of malignancy
Crook, M. K., & Guise, T. A. (2009) · IBMS BoneKEy · doi:10.1138/20090396 · Cited by 1
Metastatic Disease to the Musculoskeletal System
Hicks, D. G. (2008) · Humana Press eBooks · doi:10.1007/978-1-59259-971-4_2 · Cited by 1
OPG, RANK and RANKL in Bone Metastasis and Cancer-Associated Osteolysis
Kostenuik, P. J. (2004) · Cancer metastasis · doi:10.1007/978-1-4020-2036-0_11 · Cited by 1
Fan, T. M. (2015) · Wiley eBooks · doi:10.1002/9781119421375.ch55 · Cited by 2
de Kort, W. W. B., Haakma, W. E., van Es, R. J. J., Gawlitta, D., Driehuis, E., Gansevoort, M., & Willems, S. M. (2023) · Research Square · doi:10.21203/rs.3.rs-2405003/v1 · Cited by 1
Nakouzi, N. A. (2011) · theses.fr (ABES) · doi:10.70675/4e4b277az83fbz4562zbae0z9f48206f14aa · Cited by 1
Metastatic spinal cord compression in prostate cancer : clinical and morphological studies
Crnalic, S. (2012) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Hałaś, A. (2010) · Publication Server of Kaiserslautern University of Technology (Kaiserslautern University of Technology)
Bedeutung von RANK-Ligand und Osteoprotegerin für den Knochenstoffwechsel
Hofbauer, L. C., & Schoppet, M. (2006) · Springer eBooks · doi:10.1007/3-540-28782-5_21
Gardner, T. A., Jimènez, J. A., Chung, L. W. K., & Kao, C. H. (2005) · Humana Press eBooks · doi:10.1007/978-1-59259-785-7_20
Metástasis costal derecha de adenocarcinoma de próstata
Espasa Font, L., Supervía, A., Bano, F., & Sarbu, M. (2012) · DOAJ (DOAJ: Directory of Open Access Journals)
Estudio del metabolismo mineral óseo en el cáncer de próstata avanzado
Flores, S. Q. (2011) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Osteoimmunology and Cancer - Clinical Implications
Terpos, E., Gkotzamanidou, M. A., Christoulas, D., & Meletios, A. (2011) · InTech eBooks · doi:10.5772/23546
Owen, S. (2014) · ORCA Online Research @Cardiff (Cardiff University)
Role of TGF-β in Osteolytic Bone Metastases
Bartholin, L., & Guise, T. A. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-293-9_7
Ciblage thérapeutique des tumeurs osseuses primitives par transfert de gène
Lamoureux, F. (2008) · OpenGrey (Institut de l'Information Scientifique et Technique)
Kendler, D. L. (2010) · Orthopedic Research and Reviews · doi:10.2147/orr.s6124
Alonso, V., de Gortázar, A. R., Martínez, F. C. P., Calahorra, F. J., & Esbrit, P. (2006) · Revista Española de Enfermedades Metabólicas Óseas · doi:10.1016/s1132-8460(06)75271-0
RANKing Lung Cancer Bone Metastasis
Peters, S., & Meylan, E. (2012) · Lung Cancer Management · doi:10.2217/lmt.12.16
Editorial: Interleukin-6: A Multifunctional Molecule in Prostate Cancer
Michalaki, V., & Waxman, J. (2004) · UroOncology · doi:10.1080/15610950310001657749
Croucher, P. I. (2004) · PubMed
Costal right metastasis of prostate adenocarcinoma
Espasa Font, L., Supervía, A., del Baño, F., & Sârbu, I. (2012)
Potential use of Aneustat for improvement of docetaxel-based therapy of advanced prostate cancer
Qu, S. (2017) · cIRcle (University of British Columbia) · doi:10.14288/1.0357970
Maurizi, A., & Rucci, N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821666-8.00051-7
Nelson, W. G., Haffner, M. C., & Yegnasubramanian, S. (2015) · Wiley eBooks · doi:10.1002/9781118468678.ch28
Cai, Y.-X., Wu, Y.-Q., Liu, J., Pan, H., Deng, W., Sun, W., Xie, C., & Huang, X.-F. (2023) · Figshare · doi:10.6084/m9.figshare.24741824
La Neuropiline-1, un nouveau biomarqueur de résistance thérapeutique du cancer de la prostate
Blanc, C. (2016) · theses.fr (ABES) · doi:10.70675/b45322c5z1cbdz42c4zba0azdb401927d53c
Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy
Younes, A., & Cerutti, A. (2007) · Humana Press eBooks · doi:10.1385/1-59259-893-5:509
Metadata
- Authors
- Brown, J. M., Corey, E., Lee, Z. D., True, L. D., Yun, T. J., Tondravi, M., & Vessella, R. L.
- Affiliations
- University of Washington (US)
- American Red Cross (US)
- Corresponding author
- Brown, Julie M
- Venue
- Urology
- Publisher
- Elsevier BV
- Published
- 2001-04
- Volume
- 57
- Issue
- 4
- Pages
- 611-616
- ISSN
- 0090-4295 (ISSN-L)
- OpenAlex
- W2114394594
- Cited by
- 234
- References
- 18
- Citations by year
- 2024: 1 · 2023: 5 · 2022: 1 · 2021: 7 · 2020: 5 · 2019: 2 · 2018: 3 · 2017: 6 · 2016: 6 · 2015: 6 · 2014: 5 · 2013: 9 · 2012: 14
- FWCI
- 5.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Urology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p50dk047656-07)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 47656-07)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- osteoprotegerin, RANK ligand, prostate cancer, bone metastasis, bone resorption, bone remodeling, tumor stromal cells, luminal cells, bone turnover
- MeSH terms
- Aged, Aged, 80 and over, Base Sequence, Bone Neoplasms, Carrier Proteins, Glycoproteins, Humans, Immunohistochemistry, Lymphatic Metastasis, Male, Membrane Glycoproteins, Middle Aged, Prostate, Prostatic Neoplasms, RNA, Messenger, Cytokines, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
